Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | PRKACG | P22612 | 1/20 | 0.52 |
| ▸ | PRKACB | P22694 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28785154 | 1.00 | PRKACA (0.52) | PRKACAPRKACGPRKACBTAAR1CSNK1D | |
| SCHEMBL30824548 | 1.00 | PRKACA (0.52) | PRKACAPRKACGPRKACBTAAR1CSNK1D | |
| SCHEMBL30370162 | 0.83 | TAAR1 (0.43) | PRKACAPRKACGPRKACBTAAR1CA1 | |
| SCHEMBL22425354 | 0.81 | PRKACA (0.52) | PRKACAPRKACGPRKACBCSNK1DCSNK1E | |
| SCHEMBL22425356 | 0.81 | PRKACA (0.52) | PRKACAPRKACGPRKACBCSNK1DCSNK1E | |
| SCHEMBL28028671 | 0.81 | PRKACA (0.59) | PRKACAPRKACGPRKACBCSNK1DCSNK1E | |
| SCHEMBL14839631 | 0.81 | PRKACA (0.52) | PRKACAPRKACGPRKACBHTR2AHTR2C | |
| SCHEMBL21723230 | 0.81 | PRKACA (0.52) | PRKACAPRKACGPRKACBTAAR1CSNK1D | |
| SCHEMBL7353494 | 0.81 | PRKACA (0.52) | PRKACAPRKACGPRKACBTAAR1CSNK1D | |
| SCHEMBL26084666 | 0.80 | HTR1A (0.51) | PRKACAPRKACGPRKACBHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107337659-A | Compounds as protein kinase modulators | 理森制药股份公司 | 2017-11-10 | — | — | CN | disclosed |
| CN-103702989-B | Novel compounds as modulators of protein kinases | 理森制药股份公司 | 2017-07-07 | — | — | CN | disclosed |
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| CN-102056927-B | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC | 2014-06-25 | — | — | CN | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| CN-102056927-A | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC | 2011-05-11 | — | — | CN | disclosed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| CN-101600689-A | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (VG) | 2009-12-09 | — | — | CN | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | PRKACA 189/4885PRKACG 258/4885PRKACB 275/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | PRKACA 183/4885PRKACG 213/4885PRKACB 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.